Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
Stack claim reviews
Peptide stack claim reviews
Popular peptide combinations get a lot of online marketing. These pages compare what is claimed against what the evidence supports, plus the UK regulatory and athlete anti-doping picture. We do not publish dosing, cycle, injection, or stacking instructions — these are claim-reviews, not protocols.
BPC-157 + TB-500 — claim review
The internet's most heavily-marketed 'healing stack'. We look at what is claimed, why it is popular, what the human evidence base actually contains, and the UK regulatory and athlete anti-doping picture.
CJC-1295 + Ipamorelin — claim review
Growth-hormone-releasing peptide combination commonly marketed for 'anti-ageing' and 'body composition'. Unlicensed in the UK, prohibited in sport, and a clear example of clinic claim drift.
Semaglutide + AOD-9604 — claim review
A licensed UK medicine paired with an unlicensed compound — a combination some clinics market without acknowledging the regulatory asymmetry. The risks of mixing a POM with a grey-market peptide.
Melanotan II + PT-141 — claim review
Two melanocortin receptor agonists marketed for tanning and sexual function. MHRA's stance, the documented side-effect profile of Melanotan II, and what a licensed alternative looks like.
GHK-Cu + BPC-157 — claim review
Skin + tissue 'regeneration' combination. Topical GHK-Cu has cosmetic evidence; injectable use and BPC-157 do not. The leap from skincare data to injectable stack is not evidence-based.
MOTS-c + NAD+ — claim review
The mitochondrial longevity story. Neither compound has Phase 3 longevity-outcome trials. NMN / NR vs IV NAD+ distinction, and why exercise still wins.
Retatrutide grey-market supply — claim review
Retatrutide is investigational; no licensed reference product exists anywhere. Grey-market identity cannot be verified. The lawful UK route is registered clinical-trial enrolment.
Epitalon + MOTS-c — claim review
The headline biohacker longevity stack. Telomerase activation + mitochondrial signalling — mechanistic story exceeds Phase 3 outcome evidence by a wide margin.
Semax + Selank — claim review
Russian-developed nootropic combination. Some Russian-jurisdiction clinical use; healthy-adult cognitive-enhancement claims unsupported by Western Phase 3 trials.
Tesamorelin metabolic stack — claim review
Tesamorelin licensed in the US for HIV-associated lipodystrophy. Off-label use in 'metabolic stacks' for cosmetic visceral fat loss outruns the licensed indication evidence.
AOD-9604 fat-loss claims — claim review
AOD-9604 failed Phase 3 obesity development but persists in clinic marketing on the GRAS food-ingredient status. The honest fat-loss evidence picture.
Thymosin Alpha-1 + LL-37 — claim review
The 'immune optimisation' combination marketed for long COVID and chronic infections. TA1 is licensed in 35+ countries for specific indications; LL-37 is essentially untested in humans.
Peptide longevity stack claims — review
The whole-category review: Epitalon, MOTS-c, Humanin, GHK-Cu, NAD+ precursors. What they have in common — heavy marketing, mechanistic story, near-zero longevity-outcome trial evidence.
Peptide recovery stack claims — review
The whole-category review: BPC-157, TB-500, injectable GHK-Cu, GH secretagogues. Why physiotherapy remains the NHS evidence-based pathway.
Peptide fat-loss stack claims — review
The whole-category review: licensed GLP-1s combined with unlicensed AOD-9604 / tesamorelin / HGH Fragment. Why combining licensed and unlicensed peptides creates new risk without published benefit.
Peptide nootropic stack claims — review
The whole-category review: Semax, Selank, DSIP, Dihexa, Cerebrolysin. Russian-jurisdiction clinical use vs Western nootropic marketing.